Cardiology etiketine sahip kayıtlar gösteriliyor. Tüm kayıtları göster
Cardiology etiketine sahip kayıtlar gösteriliyor. Tüm kayıtları göster

10 Nisan 2014 Perşembe

Cardiology And The Medicare Data Avalanche

The avalanche of data released by Medicare on Wednesday was followed shortly by an avalanche of information reviews about the data. Here’s a evaluation of some of the a lot more important cardiology-relevant details that came out in these stories.


Cardiology was the third in a New York Occasions list of complete Medicare payments received by the highest-paid 2% of medical professionals. This 2% accounted for practically a single-fourth of total Medicare payments. There were two,176 cardiologists in the top two% group and they acquired much more than 1.6 billion bucks from Medicare. Ahead of cardiologists at the prime of the listing had been ophthalmologists (2,995 suppliers who received far more than $ 3.three billion) and hematologists/oncologists (one,831 suppliers who received far more than $ 2 billion).


The Washington Post‘s Wonkblog asked the leading ten Medicare billers to explain their fees



Vasso Gadioli, a vascular surgeon from Bay City, Mich., is No. six on the record with $ 10.1 million. He said he gets paid about $ three,000 per procedure for inserting stents in his workplace, but he explained he is still conserving Medicare income. If he did the method in a hospital, he will get $ 500 and the hospital receives $ eight,000, Gadioli mentioned.


About 70 % of Medicare payments to Gadioli went to overhead. Then he has to element in other charges, like employee salaries and taxes.


“Roughly a surgeon will consider home ten cents a dollar,” explained Gadioli, who has been in practice 12 years. “If I earned for myself one-tenth of [$ ten million], that’s fairly excellent.”



Asad Qamar, a cardiologist who banked the second-highest Medicare payout in 2012 at $ 18.two million, drew scrutiny last year when Reuters reported he produced a major donation to Organizing for America as he complained to government officials about the Wellness and Human Companies overview of his billing practices. A attorney representing the Institute of Cardiovascular Excellence in Ocala, Fla., defended Qamar in a Wednesday evening statement.


“ICE and its principal physician, Dr. Asad Qamar, an interventional cardiovascular subspecialist, serve a heavily-concentrated Medicare population by providing a variety of state-of-the-artwork cardiovascular interventional procedures and companies to individuals with advanced peripheral vascular arterial ailment,” wrote Tracy Mabry, an attorney for ICE. “All of ICE’s Medicare claims for this kind of procedures and services are subject to thorough pre-payment review of supporting medical documentation by Medicare’s designated contractors serving Florida, and individuals claims should meet established coverage policies of the Medicare program prior to and as a problem of their payment to ICE by Medicare.”



Qamar was also featured in a New York Times story that targeted on the political ties and contributions of best Medicaid billers:



Yet another doctor, Dr. Asad Qamar, an interventional cardiologist in Ocala, Fla., has sent at least $ 250,000 in donations more than the last decade to the political campaigns of President Obama and other prominent Democrats he has become the target of scrutiny relevant to cardiovascular remedy centers he runs in Central Florida.


Dr. Qamar was paid a lot more than $ 18 million in 2012, creating him and Dr. Melgen by far the greatest payment recipients nationwide, according to the data. A pathologist from New Jersey acquired the third largest Medicare reimbursement, $ 12.6 million.


In an interview on Wednesday, Dr. Qamar mentioned any queries about his Medicare expenses were unjustified.


“Just looking at the sheer volume of perform and billings from a single physician is not a signal of wrongdoing,” Dr. Qamar stated, noting that his practice handles cardiac procedures in its outpatient clinics that would be completed within a hospital in many other states, which he mentioned explained the big billable amounts.





The income paid to Dr. Qamar in 2012 — $ 18.two million — is much a lot more than to any other cardiologist in the United States. The second-highest total is listed as $ 4.5 million, paid to Dr. Ashish Pal of Davenport, Fla.


Dr. Pal stated in an interview on Wednesday that his billing was completely appropriate and fair, though he acknowledged it was high since he has several cardiology-related specialties, and simply because he performs in an outpatient setting and bills the government for facility fees.


Dr. Qamar stated his payments were high because his practice, which has 150 staff and a caseload of 23,000 patients, routinely handles complex procedures like opening blocked arteries in the legs of older sufferers, which normally would be billed by a hospital.


Dr. Qamar has sent far more than $ one hundred,000 to the Democratic National Committee and other state-primarily based branches of the Democratic Celebration close to the United States, and has donated to President Obama’s presidential campaigns and groups with ties to Mr. Obama, federal records display. He has also created donations to congressional candidates — practically all of them Democrats — from Nevada, Pennsylvania, Indiana, Iowa and Florida, amid other states, the records display.



The Wall Street Journal quoted Peter Rentrop, a pioneer of fibrinolysis (he was the initial particular person to provide intracoronary streptokinase to interrupt a heart attack) who now has a extremely productive cardiac imaging  practice that performs a good deal of PET imaging:



Klaus P. Rentrop, healthcare director of an imaging concern in New York City known as Gramercy Cardiac Diagnostic Companies, was listed as the ninth best recipient of Medicare payments for cardiology. The program paid him $ 2.73 million for 18,034 claims filed for two,321 individuals, the information show.


Dr. Rentrop stated he was “honored” by the placement. He said the PET imaging companies he and his colleagues provide, whilst much more pricey than other imaging tests, far more accurately demonstrate the presence or absence of cardiovascular condition and as a result minimize the amount of sufferers who are referred to hospitals for far more high-priced and invasive tests named cardiac catheterizations.




Cardiology And The Medicare Data Avalanche

31 Ocak 2014 Cuma

American University of Cardiology Announces Late-Breaking Clinical Trials

The American School of Cardiology announced the lineup of late-breaking clinical trials for its approaching yearly meeting in Washington, DC. The opening session will incorporate the most eagerly anticipated trials– the main outcomes of  Symplicity HTN-three and the  comparison of Corevalve and surgical procedure in substantial threat sufferers. Subsequent sessions will include many phase 3 trials of  PCSK9 inhibitors. Right here is the total record of trials:


ACC.14 Opening Showcase and the Joint ACC/JACC Late-Breaking Clinical Trials



  • March 29, 2014, eight:00 – ten:00 AM

  • Chair: John Gordon Harold

  • Panelists: Valentin Fuster. David E. Kandzari. Sanjay Kaul. Michael J. Mack


9:ten – 9:25 AM 451-13 - A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic Valve Substitute in Individuals with Significant Aortic Stenosis Deemed Higher-Risk for Surgical procedure



  • David H. Adams, Michael J. Reardon, Steven J. Yakubov, Joseph S. Coselli, G. Michael Deeb, Thomas G. Gleason, Maurice Buchbinder, Blase Carabello, James Hermiller, Jr., Patrick W. Serruys, Neal S. Kleiman, Stanley Chetcuti, John Heiser, William Merhi, George Zorn, Peter Tadros, Newell Robinson, George Petrossian, G. Chad Hughes, J. Kevin Harrison, John Conte, Jae K. Oh, Jeffrey J. Popma, Mount Sinai Healthcare Center, New York, NY, USA


9:35 – 9:50 AM 451-15 - The Principal Benefits of SYMPLICITY HTN-three



  • Deepak L. Bhatt, David Kandzari, William O’Neill, Ralph D’Agostino, Murray Esler, John Flack, Barry Katzen, Martin Leon, Minglei Liu, Laura Mauri, Manuela Negoita, Suzanne Oparil, Krishna Rocha-Singh, Paul Sobotka, Raymond Townsend, George Bakris, for the SYMPLICITY HTN-3 Investigators, Brigham and Women’s Hospital Heart and Vascular Center, Boston, MA, USA, University of Chicago, Chicago, IL, USA


Joint American University of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials



  • March 30, 2014, eight:00 – 9:15 AM Hall D (Primary Tent)

  • Co-Chairs: Howard C. Bauchner, Prediman K. Shah

  • Panelists: Joseph S. Alpert, Roger S. Blumenthal, Jeffrey T. Kuvin, Roxana Mehran, Nathan D. Wong


8:00 – eight:10 AM 402-08 - Result of Inhibition of Lipoprotein-Linked Phospholipase A2 with Darapladib on Ischemic Events in Sufferers with Chronic Coronary Heart Condition: The STABILITY (STabilisation of Atherosclerotic plaque By Initiation of darapLadIb Therapy) Trial



  • Harvey D. White, Claes Held, Ralph Stewart, Philippe Steg, Andrzej Budaj, Robert Harrington, Elizabeth Tarka, Rebekkah S. Brown, Christopher Cannon, Lars Wallentin, the STABILITY Investigators., Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand, Uppsala Clinical Analysis center, Uppsala, Sweden


8:15 – eight:25 AM 402-ten - The Low-density Lipoprotein Cholesterol Evaluation With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy – 2 Trial: A Phase 3, Double-blind, Randomized, Placebo and Ezetimibe Managed, Multicenter Review to Assess Security, Tolerability and Efficacy of Evolocumab (AMG 145) in Combination With Statin Treatment in Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia



  • Jennifer Robinson, Bettina S. Nedergaard, William Rogers, Jonathan Fialkow, Joel Neutel, David Ramstad, Ransi Somaratne, Jason Legg, Patric Nelson, Robert Scott, Scott Wasserman, Robert Weiss, for the LAPLACE-2 Investigators, Amgen Inc., Thousand Oaks, CA, USA


8:30 – 8:40 AM 402-twelve - Evaluation of the Dual PPAR-αγ Agonist Aleglitazar to Minimize Cardiovascular Occasions in Individuals with Acute Coronary Syndrome and Sort 2 Diabetes Mellitus: the AleCardio Trial



  • A. Michael Lincoff, Jean Claude Tardif, Bruce Neal, Stephen Nicholls, Lars Ryden, Gregory Schwartz, Klas Malmberg, John Buse, Robert Henry, Hans Wedel, Arlette Weichert, Anders Svensson, Ruth Cannata, Diederick Grobbee, AleCardio Examine Investigators, Cleveland Clinic, Cleveland, OH, USA


8:45 – eight:55 AM 402-14 - Two-yr End result of a Trial Comparing Second Generation Drug-eluting Stents Making use of Either Biodegradable Polymer or Resilient Polymer: the NOBORITM Biolimus-Eluting versus XIENCETM/PROMUSTM Everolimus-eluting Stent Trial (Up coming)



  • Masahiro Natsuaki, Ken Kozuma, Takeshi Morimoto, Kazushige Kadota, Toshiya Muramatsu, Yoshihisa Nakagawa, Takashi Akasaka, Keiichi Igarashi, Kengo Tanabe, Yoshihiro Morino, Tetsuya Ishikawa, Hideo Nishikawa, Masaki Awata, Mitsuru Abe, Hisayuki Okada, Yoshiki Takatsu, Nobuhiko Ogata, Kazuo Kimura, Kazushi Urasawa, Yasuhiro Tarutani, Nobuo Shiode, Takeshi Kimura, Kyoto University, Kyoto, Japan, Saiseikai Fukuoka Common Hospital, Fukuoka, Japan


9:00 – 9:10 AM 402-sixteen - A Phase 3 Double-blind, Randomized Review to Assess the Security and Efficacy of Evolocumab (AMG 145) in Hypercholesterolemic Subjects Unable to Tolerate an Successful Dose of Statin



  • Erik S.G. Stroes, David Colquhoun, David Sullivan, Fernando Civeira, Robert Rosenson, Gerald F. Watts, Eric Bruckert, Ricardo Dent, Allen Xue, Robert Scott, Scott Wasserman, Michael Rocco, GAUSS-two Investigators, Amgen Inc., Thousand Oaks, CA, USA


Late-Breaking Clinical Trials III



  • March thirty, 2014, ten:45 – 12:00 PM Hall D (Principal Tent)

  • Co-Chairs: Rick A. Nishimura, Evan M. Zahn

  • Panelists: George L. Bakris, Massimo Imazio, Allan S. Jaffe, Michael Shehata, Ronald G. Victor


ten:45 – 10:fifty five AM 403-08 - Efficacy And Safety Of Colchicine In Patients With Several Recurrences Of Pericarditis: Final results Of A Multicenter, Double-blind, Placebo-managed, Randomized Research (corp-two Trial).



  • Massimo Imazio, Riccardo Belli, Antonio Brucato, Roberto Cemin, Stefania Ferrua, Yehuda Adler, David H. Spodick, Rita Trinchero, Cardiology Division, Maria Vittoria Hospital, Torino, Italy


11:00 – eleven:10 AM 403-ten - The Worldwide SYMPLICITY Registry: Security and Effectiveness of Renal Artery Denervation In Actual Globe Individuals With Uncontrolled Hypertension



  • Michael Bohm, Markus Schlaich, Krzysztof Narkiewicz, Luis Ruilope, Bryan Williams, Roland Schmieder, Felix Mahfoud, Giuseppe Mancia, Universitätskliniken des Saarlandes, Klinik für Innere Medizin III, Homburg/Saar, Germany


eleven:15 – 11:25 AM 403-12 - A single 12 months Adhere to-up of the Melody Transcatheter Pulmonary Valve Multicenter Publish Approval Review



  • Aimee K. Armstrong, David Balzer, Allison Cabalka, Robert Gray, Alexander Javois, Jacqueline Kreutzer, John Moore, Jonathan Rome, Daniel Turner, Thomas Zellers, University of Michigan C.S. Mott Children’s Hospital, Ann Arbor, MI, USA, Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA


eleven:thirty – eleven:40 AM 403-14 - Lengthy-term Survival with Cardiac Resynchronization Treatment in Individuals with Mild Heart Failure



  • Ilan Goldenberg, Valentina Kutyifa, Helmut Klein, Scott McNitt, Scott Solomon, Arthur Moss, MADIT-CRT Executive Committee, University of Rochester Health-related Center, Rochester, NY, USA, Sheba Healthcare Center, Tel Hashomer, Israel


11:45 – eleven:55 AM 403-16 - Adverse High-Delicate Troponins in the Emergency Department and Risk of Myocardial Infarction



  • Nadia Bandstein, Magnus Johansson, Rickard Ljung, Martin Holzmann, Karolinska Institutet, Stockholm, Sweden


Joint American University of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials



  • March 31, 2014, eight:00 – 9:15 AM Hall D (Primary Tent)

  • Co-Chairs: John A. Jarcho, Steven E. Nissen

  • Panelists: Yochai Birnbaum, Scott Cunneen, Michael H. Davidson, D. Craig Miller, Freek W. A. Verheugt


eight:00 – eight:10 AM 404-08 - The Influence of Acetyl-Salicylic Acid on Main Arterial and Venous Problems in Patients Undergoing Noncardiac Surgery



  • P.J. Devereaux, POISE-two Investigators, Population Health Research Institute, Hamilton, Canada


eight:15 – 8:25 AM 404-ten - A Big Global Trial Assessing the Results of Clonidine on Significant Arterial Events in Individuals Obtaining Noncardiac Surgical treatment



  • Daniel I. Sessler, P.J. Devereaux, POISE-2 Investigators, Outcomes Research, Cleveland Clinic, Cleveland, OH, USA


8:30 – 8:40 AM 404-twelve - Steroids in Cardiac Surgical procedure Trial (SIRS)



  • Richard Whitlock, Population Overall health Study Institute, McMaster University/Hamilton Overall health Sciences, Hamilton, Canada


eight:45 – 8:55 AM 404-14 - Metformin in Acute Myocardial Infarction



  • Chris PH Lexis, Iwan CC van der Horst, Erik Lipsic, Jan Tijssen, Pim van der Harst, Dirk van Veldhuisen, GIPS-III Investigators, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, Academic Health care Center, University of Amsterdam, Amsterdam, The Netherlands


9:00 – 9:ten AM 404-16 - Effect of Bariatric Surgical procedure vs. Intensive Medical Treatment on Extended-phrase Glycemic Manage and Complications of Diabetes: 3-Year STAMPEDE Trial Final results



  • Philip Raymond Schauer, John Kirwan, Kathy Wolski, Stacy Brethauer, Sankar Navaneethan, Ali Aminian, Claire Pothier, Steven Nissen, Deepak Bhatt, Sangeeta Kashyap, Cleveland Clinic, Cleveland, OH, USA


Late-Breaking Clinical Trials V: TCT@ACC-i2



  • March 31, 2014, 10:45 – twelve:00 PM Hall D (Major Tent)

  • Co-Chairs: Cindy L. Grines, David E. Kandzari

  • Panelists: David L. Brown, David E. Kandzari, Dean J. Kereiakes, Roxana Mehran, William W. O’Neill


10:45 – 10:55 AM 405-08 - One Year Outcomes from the STS/ACC Transcatheter Valve Therapy (TVT) Registry



  • David R. Holmes, J. Matthew Brennan, John Rumsfeld, Dadi (David) Dai, Fred Edwards, John Carroll, David Shahian, Frederick Grover, E. Murat Tuzcu, Eric Peterson, Ralph Brindis, Michael Mack, Mayo Clinic, Rochester, MN, USA


11:00 – eleven:10 AM 405-10 - A Randomized Comparison of Self-Expandable and Balloon-Expandable Prostheses in Patients Undergoing Transfemoral Transcatheter Aortic Valve Substitute – The Choice Trial



  • Mohamed Abdel-Wahab, Julinda Mehilli, Ulrich Schäfer, FJ Neumann, Thomas Kurz, Ralph Toelg, Bettina Schwarz, Ken Gordian, Volker Geist, Steffen Massberg, Christian Frerker, Mohamed El-Mawardy, Gert Richardt, Heart Center, Segeberger Kliniken, Bad Segeberg, Germany


11:15 – eleven:25 AM 405-12 - Unfractionated Heparin versus Bivalirudin in Main Percutaneous Coronary Intervention: A Exclusive Randomized Controlled Trial with Consecutive, Unselected Patient Enrollment (using Delayed Consent), Developed to Reflect True-Planet, Contemporary Practice



  • Adeel Shahzad, Ian Kemp, Christine Mars, Rob Cooper, Claire Roome, Keith Wilson, Rod Stables, HEAT-PPCI investigators, Institute of Cardiovascular Medicine and Science, Liverpool Heart and Chest Hospital NHS Believe in, Liverpool, United Kingdom


11:thirty – eleven:40 AM 405-14 - Bare Metal vs. Zotarolimus-eluting stent in Uncertain Drug-eluting Stent Candidates: A Randomized Controlled Trial



  • Marco Valgimigli, ZEUS investigators, , Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands


eleven:45 – eleven:fifty five AM 405-16 - Autotransplantation of Bone Marrow Derived Mesenchymal Stromal Cells in Individuals with Extreme Ischemic Heart Failure: The MSC-HF Trial



  • Anders Bruun Mathiasen, Abbas Qayyum, Erik Jørgensen, Steffen Helqvist, Anne Fischer-Nielsen, Klaus Kofoed, Mandana Haack-Sørensen, Annette Ekblond, Jens Kastrup, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, Denmark



American University of Cardiology Announces Late-Breaking Clinical Trials